Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11530890 | 0.72 | CCNE2 (0.31) | — | |
| SCHEMBL24557235 | 0.72 | MAPT (0.32) | MAPT | |
| SCHEMBL21899216 | 0.72 | GLP1R (0.32) | — | |
| SCHEMBL11525636 | 0.71 | KDM4E (0.39) | GAAKDM4EALDH1A1MAPT | |
| SCHEMBL5610248 | 0.70 | — | — | |
| SCHEMBL11530766 | 0.70 | LOXL2 (0.36) | KDM4EALDH1A1PTGS2 | |
| SCHEMBL11530685 | 0.69 | TXNRD1 (0.38) | MAPT | |
| SCHEMBL11531114 | 0.69 | HSD11B1 (0.50) | HSD11B1GAAKDM4EALDH1A1PTGS2 | |
| SCHEMBL8366938 | 0.68 | HSD11B1 (0.51) | HSD11B1KDM4EALDH1A1 | |
| SCHEMBL3464904 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| WO-2020198710-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA, INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-08-06 | — | — | US | disclosed |
| US-4143047-A | 2-SULFINYL AND 2-SULFONYL OXAZOLES | LILLY INDUSTRIES LIMITED (GB) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | HSD11B1 12/4885GAA 3582/4885KDM4E 3774/4885 |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | AR, NR5A1, CYP17A1 | HSD11B1 12/4885GAA 3582/4885KDM4E 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.